Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) was the target of some unusual options trading activity on Tuesday. Stock traders bought 728 put options on the stock. This represents an increase of 777% compared to the typical daily volume of 83 put options.
In related news, COO Bruce D. Given sold 20,000 shares of the company’s stock in a transaction dated Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the transaction, the chief operating officer now directly owns 948,356 shares in the company, valued at $3,499,433.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.60% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of ARWR. Vanguard Capital Wealth Advisors bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $119,000. Macquarie Group Ltd. bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $123,000. Jane Street Group LLC bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $130,000. Two Sigma Investments LP bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $146,000. Finally, Virtu KCG Holdings LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 53,215 shares during the last quarter. 25.46% of the stock is owned by institutional investors and hedge funds.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative return on equity of 42.52% and a negative net margin of 116.17%. The firm had revenue of $8.71 million for the quarter, compared to the consensus estimate of $7.32 million. analysts expect that Arrowhead Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.
ARWR has been the topic of several research reports. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, February 19th. BidaskClub cut shares of Arrowhead Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. Cantor Fitzgerald set a $2.00 price objective on shares of Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, December 12th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, B. Riley initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $4.70.
COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals Target of Unusually High Options Trading (ARWR)” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3227580/arrowhead-pharmaceuticals-target-of-unusually-high-options-trading-arwr.html.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.